New approaches may prevent certain side effects in BRAF mutation-positive melanoma
Sunday, November 13, 2011 - 17:30
in Health & Medicine
Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, may have the potential to prevent drug-induced skin lesions in BRAF mutation-positive patients treated for melanoma.